Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 210, Issue 7, Pages 1073-1082Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiu113
Keywords
enterovirus 71 vaccine; booster immunization; immunogenicity and safety
Categories
Funding
- China 12-5 National Major Infectious Disease Programs [2012ZX10004-703, 2012ZX10002-001]
- Beijing Vigoo Biological
Ask authors/readers for more resources
Background. A significant waning of enterovirus 71 (EV71) antibody titer after priming immunization with an inactivated EV71 vaccine implied the potential need for a booster dose. Methods. In this randomized, double-blind, placebo-controlled clinical trial, we recruited participants who had received at least 1 dose of priming EV71 vaccine in an early phase 2 clinical trial that was conducted in healthy infants and children aged 6-35 months. All participants were grouped according to the priming EV71 vaccine formulations (160 U, 320 U, and 640 U with adjuvant and 640 U without adjuvant) and then randomly assigned (ratio, 2: 1) to receive a booster dose of vaccine or placebo within each formulation group. The primary end point was the geometric mean titer 28 days after the booster dose. Results. A total of 773 participants were enrolled. Significantly greater immunological responses were induced by the booster shot of all 4 formulations of EV71 vaccine, compared with that induced by placebo (P <.0001). The frequencies of adverse reactions were similar between vaccine and placebo groups within each formulation group. Conclusions. A booster dose of EV71 vaccine 1 year after the priming EV71 immunization shows excellent immunogenicity and good safety profile. Clinical Trials Registration. NCT01734408.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available